Arbele's Remarkable Victory at the Annual Biomedical Pitch Competition
Arbele Limited, a pioneering biotech company based in Hong Kong, recently achieved a significant milestone by winning first place at the prestigious 4th Biomedical Pitch Competition organized by the Boston Capital Investment Club (BCIC). With over 170 competitors from various parts of the globe, Arbele distinguished itself through its innovative research in CDH17-targeted immunotherapy and antibody-drug conjugate (ADC) technology.
The company is dedicated to advancing novel therapies for gastrointestinal cancers by specifically targeting cadherin-17 (CDH17), a marker that is prominently expressed in malignancies affecting the digestive tract. Among its crown jewels is Cabotamig (ARB202), a groundbreaking T-cell engager designed to simultaneously bind to CDH17 and CD3, aimed at offering treatment for a wide range of gastrointestinal cancers. This promising therapy has exhibited high safety regarding tumor targeting and improved survival outcomes in patients with challenging medical backgrounds resembling other T-cell engagers noted in Phase I clinical studies.
Beyond just Cabotamig, Arbele is furthering its research with multiple ADC programs that include biparatopic and bispecific targets combined with novel dual payloads. The company is preparing for planned regulatory submissions in both the U.S. and China, reinforcing its commitment to bring advanced treatments to market. The judges at the competition praised Arbele's innovative platform for effectively balancing tumor targeting specificity while minimizing the potential for off-target toxicity, highlighting its readiness for real-world clinical application.
The event featured inspiring keynote addresses from industry leaders, including Mr. Albert Wong, CEO of the Hong Kong Science and Technology Parks Corporation (HKSTP). He shared valuable insights regarding the ongoing growth of Hong Kong's biomedical ecosystem and cross-border innovations. Dr. Qiusong Tang, Head of the Roche Accelerator, also provided perspective on the importance of scalable startups and external innovation strategies within reputable organizations like Roche.
Intense Competition with Global Implications
The impressive turnout at the 2025 competition, which saw over 170 applications, culminated in 17 finalist teams. Arbele's achievement not only symbolizes substantial international acknowledgment for its CDH17-targeting platform but also fuels its fundraising, regulatory, and commercialization initiatives.
Since its inception in 2022, the competition has facilitated impressive investments surpassing $100 million, marking a significant impact on the biotech landscape.
Overview of Arbele
Arbele Limited is on the forefront as a clinical-stage biotechnology company, dedicated to developing revolutionary first-in-class and best-in-class immunotherapies aimed at combating digestive tract cancers. With a focused commitment to CDH17-targeted T-cell engagers and ADCs, Arbele aspires to enhance survival rates among patients with limited treatment alternatives.
About BCIC
The Boston Capital Investment Club (BCIC) serves as a vital connector for early-stage companies and over 300 institutional and angel investors on a global scale. With extensive expertise in areas such as business development, incubation, and establishing strategic partnerships, BCIC has solidified its status as one of North America’s foremost unified cross-border investment platforms.
For Press Contact:
Dr. Diana Hay
For BD & Partnering Inquiries:
Mr. Alex Wang
Frequently Asked Questions
What recent recognition did Arbele achieve?
Arbele recently won first place in the 4th Biomedical Pitch Competition organized by the Boston Capital Investment Club.
What is Arbele developing?
Arbele is focused on developing innovative treatments for gastrointestinal cancers using CDH17-targeted therapies.
Who were the keynote speakers at the competition?
Keynote speakers included Mr. Albert Wong from HKSTP and Dr. Qiusong Tang from Roche.
How many companies competed in the competition?
Over 170 companies applied for the competition, with 17 finalists selected.
What is the mission of Arbele?
Arbele aims to improve survival outcomes for patients with limited treatment options through advanced immunotherapies.
